伊立替康联合顺铂治疗晚期非小细胞肺癌的临床研究
[Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
作者信息
Han Na, Liu Zong-wen, Wang Jian, Zhang Zhong-mian
机构信息
Department of Oncology, Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
出版信息
Nan Fang Yi Ke Da Xue Xue Bao. 2010 Feb;30(2):349-50.
OBJECTIVE
To evaluate the efficacy and adverse effects of irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).
METHODS
Fifteen patients (10 males and 5 females) aged from 32 to 58 years (median age of 47 years) with KPS>70 and the diagnosis of advanced NSCLC by pathology or cytology were treated with cisplatin 80 mg/m(2) plus irinotecan 60 mg/m(2) by intravenous infusion on 1, 8, 15 days, and the treatment was repeated every 4 weeks. After treatment for at least 2 cycles, the therapeutic effects and adverse drug reactions were evaluated.
RESULTS
Of all the cases, PR was achieved in 4 (26.7%), SD in 9 (60%), and PD in 2 (13.3%), with an overall response rate of 26.7%. The median survival time was 11 months and 1-year survival rate was 46.7% (7/15). The main toxicities were delayed diarrhea and granulocytopenia.
CONCLUSION
Irinotecan plus cisplatin is an effective and tolerable treatment for advanced NSCLC with low incidence of adverse effects.
目的
评估伊立替康联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应。
方法
15例年龄32至58岁（中位年龄47岁）、KPS>70且经病理或细胞学确诊为晚期NSCLC的患者，于第1、8、15天静脉输注顺铂80mg/m²加伊立替康60mg/m²，每4周重复治疗。治疗至少2个周期后，评估治疗效果及药物不良反应。
结果
所有病例中，4例（26.7%）达到部分缓解（PR），9例（60%）疾病稳定（SD），2例（13.3%）疾病进展（PD），总缓解率为26.7%。中位生存时间为11个月，1年生存率为46.7%（7/15）。主要毒性为延迟性腹泻和粒细胞减少。
结论
伊立替康联合顺铂是治疗晚期NSCLC的一种有效且耐受性良好的方案，不良反应发生率低。
Zotero 插件